Eisai is pleased to announce the availability of the fifth comic book in the “Medikidz Explain Epilepsy” series, “Medikidz Explain Lennox-Gastaut Syndrome (LGS),” an educational comic…
NOW ACCEPTING APPLICATIONS CURE 2017 Cycle 1 Funding Opportunities CURE is now accepting LOIs for our first 2017 grant cycle. Innovator Award – $50,000 USD…
Attention research teams: The NIH/NNHLBI recently announced a research project grant for perinatal stroke. This Funding Opportunity Announcement (FOA) solicits grant applications regarding basic or translational research…
London, UK; 26 Sept 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: “GWP,” “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing…
At the Child Neurology Foundation (CNF), our mission is to serve as a collaborative center of education and support for children living with neurologic conditions…
The 2016 PCORI Annual Meeting is taking place in November in the greater Washington, D.C. area, and we’re offering scholarships to help patients, caregivers, and…
Consumer Stipend Funds The Arc of Illinois, through a grant from the Illinois Council on Developmental Disabilities, administers the Consumer Involvement Program and distributes consumer stipend…
Requirements for Scholarship: Must be a college student living with a neurological disorder. Must be enrolled as full time student. The limitations are not bound…
First and only FDA-approved botulinum toxin for the treatment of pediatric lower limb spasticity and studied in patients with cerebral palsy Pivotal study in cerebral…
The Child Neurology Foundation (CNF) is pleased to announce the publication of a new consensus statement endorsed by the American Academy of Neurology (AAN), Child Neurology…
Enroll for Epilepsy Genetics Initiative today! Two new enrollment partners added EGI continues building upon the promise to tirelessly search for new ways of understanding the…
– Primary endpoint achieved with high statistical significance (p=0.0135) showing that Epidiolex treatment reduces drop seizures compared to placebo – – Today’s LGS data follows…
Eisai Inc. announced today the availability of FYCOMPA® (perampanel) Oral Suspension, a new bioequivalent interchangeable alternative to the FYCOMPA tablet for patients who have difficulty…
In collaboration with the U.S. Department of Defense, CURE is excited to launch a NEW research program to support a collaborative, milestone-driven approach to advance…